International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.

Détails

ID Serval
serval:BIB_6C03E818DE0B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.
Périodique
European journal of nuclear medicine and molecular imaging
Auteur⸱e⸱s
Levillain H., Bagni O., Deroose C.M., Dieudonné A., Gnesin S., Grosser O.S., Kappadath S.C., Kennedy A., Kokabi N., Liu D.M., Madoff D.C., Mahvash A., Martinez de la Cuesta A., Ng DCE, Paprottka P.M., Pettinato C., Rodríguez-Fraile M., Salem R., Sangro B., Strigari L., Sze D.Y., de Wit van der Veen B.J., Flamen P.
ISSN
1619-7089 (Electronic)
ISSN-L
1619-7070
Statut éditorial
Publié
Date de publication
05/2021
Peer-reviewed
Oui
Volume
48
Numéro
5
Pages
1570-1584
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
A multidisciplinary expert panel convened to formulate state-of-the-art recommendations for optimisation of selective internal radiation therapy (SIRT) with yttrium-90 ( <sup>90</sup> Y)-resin microspheres.
A steering committee of 23 international experts representing all participating specialties formulated recommendations for SIRT with <sup>90</sup> Y-resin microspheres activity prescription and post-treatment dosimetry, based on literature searches and the responses to a 61-question survey that was completed by 43 leading experts (including the steering committee members). The survey was validated by the steering committee and completed anonymously. In a face-to-face meeting, the results of the survey were presented and discussed. Recommendations were derived and level of agreement defined (strong agreement ≥ 80%, moderate agreement 50%-79%, no agreement ≤ 49%).
Forty-seven recommendations were established, including guidance such as a multidisciplinary team should define treatment strategy and therapeutic intent (strong agreement); 3D imaging with CT and an angiography with cone-beam-CT, if available, and <sup>99m</sup> Tc-MAA SPECT/CT are recommended for extrahepatic/intrahepatic deposition assessment, treatment field definition and calculation of the <sup>90</sup> Y-resin microspheres activity needed (moderate/strong agreement). A personalised approach, using dosimetry (partition model and/or voxel-based) is recommended for activity prescription, when either whole liver or selective, non-ablative or ablative SIRT is planned (strong agreement). A mean absorbed dose to non-tumoural liver of 40 Gy or less is considered safe (strong agreement). A minimum mean target-absorbed dose to tumour of 100-120 Gy is recommended for hepatocellular carcinoma, liver metastatic colorectal cancer and cholangiocarcinoma (moderate/strong agreement). Post-SIRT imaging for treatment verification with <sup>90</sup> Y-PET/CT is recommended (strong agreement). Post-SIRT dosimetry is also recommended (strong agreement).
Practitioners are encouraged to work towards adoption of these recommendations.
Mots-clé
Embolization, Therapeutic, Humans, Liver Neoplasms/radiotherapy, Microspheres, Positron Emission Tomography Computed Tomography, Technetium Tc 99m Aggregated Albumin, Yttrium Radioisotopes/therapeutic use, Dosimetry, Liver tumours, Recommendations, SIRT
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2021 9:58
Dernière modification de la notice
09/01/2024 8:15
Données d'usage